• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Foghorn Therapeutics Inc.

    4/30/26 7:05:09 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FHTX alert in real time by email
    DEFA14A 1 d151433ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    FOGHORN THERAPEUTICS INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    Foghorn Therapeutics Inc. Annual Meeting of Stockholders Wednesday, June 24, 2026 9:00 AM, Eastern Time Annual Meeting to be held live via the internet—please visit www.proxydocs.com/FHTX for more details. To attend the meeting online and/or participate, you must register at www.proxydocs.com/FHTX For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/FHTX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 12, 2026. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 24, 2026 For stockholders of record as of April 27, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/FHTX Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions.


    LOGO

    Foghorn Therapeutics Inc. Annual Meeting of Stockholders The Board of Directors recommends a vote FOR each of the director nominees in Proposal 1, FOR Proposals 2 and 3, and for 1 YEAR on Proposal 4. PROPOSAL 1. Elect Class III directors each for a three-year term 1.01 Douglas Cole, M.D. 1.02 Balkrishan (Simba) Gill, Ph.D. 1.03 B. Lynne Parshall 2. To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. 3. To approve, on an advisory basis, the compensation of Foghorn’s named executive officers. 4. To approve, on an advisory basis, the frequency of future advisory votes on the compensation of Foghorn’s named executive officers.

    Get the next $FHTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX

    DatePrice TargetRatingAnalyst
    2/17/2026$12.00Buy
    Jefferies
    12/18/2025$11.00Buy
    BTIG Research
    11/7/2025$12.00Buy
    Guggenheim
    9/17/2025$10.00Buy
    B. Riley Securities
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    1/30/2025$10.00Buy
    B. Riley Securities
    9/3/2024$18.00Buy
    Jefferies
    8/19/2024$20.00Outperform
    Evercore ISI
    More analyst ratings

    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

    WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright

    5/12/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

    - FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory  - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical

    5/7/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

    - Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer - Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy - Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a c

    4/21/26 4:05:00 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.

    SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    5/15/26 4:09:37 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.

    SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    5/14/26 6:20:30 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Foghorn Therapeutics Inc.

    10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

    5/7/26 7:02:59 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gottschalk Adrian

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    4/13/26 4:01:20 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Maynard Ryan D

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:02:39 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Maynard Ryan D

    3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:01:09 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Foghorn Therapeutics with a new price target

    Jefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    2/17/26 7:49:23 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Foghorn Therapeutics with a new price target

    BTIG Research initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $11.00

    12/18/25 9:11:03 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Foghorn Therapeutics with a new price target

    Guggenheim initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    11/7/25 8:30:10 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Leadership Updates

    Live Leadership Updates

    View All

    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. "I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, Pres

    2/23/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ted Myles Joins Cellarity as Chief Executive Officer

    Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

    5/12/25 8:00:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    10/8/24 5:44:34 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Foghorn Therapeutics Inc.

    SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)

    9/20/24 6:00:44 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    6/10/24 9:48:22 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Financials

    Live finance-specific insights

    View All

    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

    First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn's drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseas

    4/9/24 4:30:00 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

    Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, inclu

    3/26/24 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care